Role of darunavir in the management of HIV infection

References

• GazzardBBernardAJBoffitoMBritish HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyHIV Med20067848750317105508
   PubMed Web of Science ®Google Scholar
• HammerSMSaagMSSchechterMTreatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelJAMA2006296782784316905788
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338138538609516219
   PubMed Web of Science ®Google Scholar
• GrabarSPradierCLe CorfecEFactors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitorAIDS200014214114910708284
   PubMed Web of Science ®Google Scholar
• WainbergMAFriedlandGPublic health implications of antiretroviral therapy and HIV drug resistanceJAMA199827924197719839643862
   PubMed Web of Science ®Google Scholar
• BrennerBRoutyJPQuanYPersistence of multidrug-resistant HIV-1 in primary infection leading to superinfectionAIDS200418121653166015280776
   PubMed Web of Science ®Google Scholar
• BrennerBGRogerMMoisiDDTransmission networks of drug resistance acquired in primary/early stage HIV infectionAIDS200822182509251519005274
   PubMed Web of Science ®Google Scholar
• TomasselliAGHeinriksonRLTargeting the HIV-protease in AIDS therapy: a current clinical perspectiveBiochim Biophys Acta200014771–218921410708858
   PubMed Web of Science ®Google Scholar
• TomasselliAGHeinriksonRLSpecificity of retroviral proteases: an analysis of viral and nonviral protein substratesMethods Enzymol19942412793017854182
   PubMed Web of Science ®Google Scholar
• WlodawerAStructure-based design of AIDS drugs and the development of resistanceVox Sang200283 Suppl 1232612617097
   PubMed Web of Science ®Google Scholar
• de MendozaCMorelloJGarcia-GascoPRodriguez-NovoaSSorianoVTipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patientsExpert Opin Pharmacother2007868395017425479
   PubMed Web of Science ®Google Scholar
• SurlerauxDLde KockHAVerschuerenWGDesign of HIV-1 protease inhibitors active on multidrug-resistant virusJ Med Chem20054861965197315771440
   PubMed Web of Science ®Google Scholar
• GhoshAKKincaidJFChoWPotent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)s ulfonamide isostereBioorg Med Chem Lett1998866876909871583
   PubMed Web of Science ®Google Scholar
• GhoshAKDawsonZLMitsuyaHDarunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIVBioorg Med Chem200715247576758017900913
   PubMed Web of Science ®Google Scholar
• GhoshAKChapsalBDWeberITMitsuyaHDesign of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistanceAcc Chem Res2008411788617722874
   PubMed Web of Science ®Google Scholar
• KovalevskyAYLouisJMAnianaAGhoshAKWeberITStructural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 proteaseJ Mol Biol2008384117819218834890
   PubMed Web of Science ®Google Scholar
• HongLZhangXCHartsuckJATangJCrystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistanceProtein Sci20009101898190411106162
   PubMed Web of Science ®Google Scholar
• LacoGSSchalk-HihiCLubkowskiJCrystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitorBiochemistry1997363510696107089271500
   PubMed Web of Science ®Google Scholar
• KovalevskyAYLiuFLeshchenkoSUltra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114J Mol Biol2006363116117316962136
   PubMed Web of Science ®Google Scholar
• Prabu-JeyabalanMNalivaikaESchifferCASubstrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexesStructure200210336938112005435
   PubMed Web of Science ®Google Scholar
• KohYNakataHMaedaKNovel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitroAntimicrob Agents Chemother200347103123312914506019
   PubMed Web of Science ®Google Scholar
• KovalevskyAYTieYLiuFEffectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90MJ Med Chem20064941379138716480273
   PubMed Web of Science ®Google Scholar
• De MeyerSAzijnHSurlerauxDTMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolatesAntimicrob Agents Chemother20054962314232115917527
   PubMed Web of Science ®Google Scholar
• SurlerauxDLTahriAVerschuerenWGDiscovery and selection of TMC114, a next generation HIV-1 protease inhibitorJ Med Chem20054861813182215771427
   PubMed Web of Science ®Google Scholar
• KingNMPrabu-JeyabalanMNalivaikaEAWigerinckPde BethuneMPSchifferCAStructural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitorJ Virol20047821120121202115479840
   PubMed Web of Science ®Google Scholar
• McKeageKPerryCMKeamSJDarunavir: a review of its use in the management of HIV infection in adultsDrugs200969447750319323590
   PubMed Web of Science ®Google Scholar
• KohYMatsumiSDasDPotent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerizationJ Biol Chem200728239287092872017635930
   PubMed Web of Science ®Google Scholar
• DierynckIDe WitMGustinEBinding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrierJ Virol20078124138451385117928344
   PubMed Web of Science ®Google Scholar
• DeJesusEGottliebMSGatheJCJrGreenbergMLGuittariCJZolopaARSafety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification studyAntimicrob Agents Chemother200852124315918809940
   PubMed Web of Science ®Google Scholar
• Agency EMPrezista URL: www.emea.europa.eu/humandocs/PDFs/.../prezista/H-707-en1.pdf2009
   Google Scholar
• BackDSekarVHoetelmansRMDarunavir: pharmacokinetics and drug interactionsAntivir Ther200813111318389894
   PubMed Web of Science ®Google Scholar
• SaxPEFDA approval: darunavirAIDS Clin Care20061887116906668
   PubMedGoogle Scholar
• RiveroACamachoAPerez-CamachoITorre-CisnerosJDarunavir in HIV/HVC/HVB coinfectionEnferm Infecc Microbiol Clin200826 Suppl 10374219195458
   PubMedGoogle Scholar
• RachlisAClotetBBaxterJMurphyRLefebvreESafety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3HIV Clin Trials20078421322017720661
   PubMed Web of Science ®Google Scholar
• YilmazAIzadkhashtiAPriceRWDarunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individualsAIDS Res Hum Retroviruses200925445746119320601
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNMolinaJMEfficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsLancet200736995681169117817416261
   PubMed Web of Science ®Google Scholar
• PozniakAOpravilMBeattyGHillAde BethuneMPLefebvreEEffect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2AIDS Res Hum Retroviruses200824101275128018844462
   PubMed Web of Science ®Google Scholar
• Denes BanhegyiCKDa CunhaCStefan SchneiderSPhase III TITAN Week 96 final analysis: efficacy/safety of darunavir/ritonavir versus lopinavir/ritonavir in lopinavir/ritonavir-naïve, treatment-experienced patients9th International Congress on Drug Therapy in HIV Infection2008Glasgow, United Kingdom2008
   Google Scholar
• SmithCJPhillipsANDauerBFactors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppressionHIV Med2009101192719018880
   PubMed Web of Science ®Google Scholar
• de MeyerSVangeneugdenTvan BaelenBResistance profile of darunavir: combined 24-week results from the POWER trialsAIDS Res Hum Retroviruses200824337938818327986
   PubMed Web of Science ®Google Scholar
• MadrugaJVBergerDMcMurchieMEfficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet20073709581495817617272
   PubMed Web of Science ®Google Scholar
• McKinnellJALinHYNevinCNEarly virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes studyAIDS2009In press
   Web of Science ®Google Scholar
• OrtizRDejesusEKhanlouHEfficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48AIDS2008221213891389718614861
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS2009In press
   Web of Science ®Google Scholar
• ArribasJRAHGestoftJFatkenheuerGfor the MONET study groupThe MONET Trial: Darunavir/ritonavir monotherapy shows non-inferiorefficacy to standard HAART, for patients with HIV RNA < 50 copies/ml at baseline5th IASConference2009Cape Town, South Africa2009
   Google Scholar
• KatlamaCVMAAlgarte-GeninMONOI A randomised multicenter study to compare efficay of a monotherapy of darunavir to a triple therapy with 2 nucleoside analoguescombined to darunavir/r in HIV infected patients with full viral suppression5th IAS2009Cape Town, South Africa2009
   Google Scholar
• MolinaJMCohenCKatlamaCSafety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3J Acquir Immune Defic Syndr2007461243117621237
   PubMed Web of Science ®Google Scholar
• TomakaFLefebvreESekarVEffects of ritonavir-boosted darunavir vs ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteersHIV Med200910531832719210693
   PubMed Web of Science ®Google Scholar
• McKinnellJALinHYNevinCNEarly virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes studyAIDS200923121539154619487910
   PubMed Web of Science ®Google Scholar
• HillAHemmettLWilsonBAnalysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trialsHIV Clin Trials20078530331017956831
   PubMed Web of Science ®Google Scholar
• HillAMSmithCAnalysis of treatment costs for HIV RNA reductions and CD4 increases for darunavir versus other antiretrovirals in treatment-experienced, HIV-infected patientsHIV Clin Trials20078312113117621459
   PubMed Web of Science ®Google Scholar
• ChenRYAccorttNAWestfallAODistribution of health care expenditures for HIV-infected patientsClin Infect Dis20064271003101016511767
   PubMed Web of Science ®Google Scholar